J&J invests $100M in Delix Therapeutics for psychedelic-inspired depression drugs

Johnson & Johnson is investing $100 million in Delix Therapeutics, a biotech developing non-hallucinogenic psychedelic-inspired treatments for depression. This signals continued corporate interest in novel psychiatric therapies, though clinical and regulatory outcomes remain uncertain.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works